Thank you, Mr. Davies.
For the benefit of Canadians watching, you have two different things going on at Royalmount. You have the $44 million for the clinical trials, and the issue that you mentioned. There was some issue with the certification, but now what we're talking about is a plant that will be able to produce two million vaccines per month.
I would say, Mr. Davies, when you have a partner like Novavax, which every country in the world would like to have, and they chose Canada and they chose Royalmount, I think that should give confidence that we will be able to produce in accordance with the timelines that have been provided.